U.S. Markets close in 1 hr 47 mins


Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
0.17-0.03 (-12.50%)
As of 3:42PM CEST. Market open.
Interactive chart
Previous Close0.20
BidN/A x N/A
AskN/A x N/A
Day's Range0.11 - 0.17
52 Week Range0.11 - 0.17
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • 24/7 Wall St.9 months ago

    5 Biohealth Stocks Rising 10% or More on News

    A few biohealth companies made absolutely massive runs in Thursday’s session. The companies 24/7 Wall St. has picked stood out from the rest with big moves, all at least up 10%.

  • Zacks Small Cap Researchlast year

    AEMD: More Shots on Goal for Hemopurifier, ESI

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2016 Financials, Operational Update  Aethlon Medical (NASDAQ:AEMD) reported financial results for their third quarter 2016 and provided an operational update.  ...

  • Zacks Small Cap Research2 years ago

    AEMD: Meets 5 Objective, New ADAPT Program To Broaden Applications

    - Submission of manuscript of the DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study.  As a reminder, since late last calendar year Aethlon’s majority-owned subsidiary Exosome Sciences (ESI) has collaborated with Boston University’s CTE Center for the development of a blood-based diagnostic that would be able to identify CTE in living individuals.  ESI has used what they learned in how to isolate certain brain-specific biomarkers to evaluate blood samples collected by participants (former NFL players and a control group) enrolled in BU's DETECT study.  The study is the first on CTE funded by the NIH.